| Literature DB >> 28499878 |
Harumasa Takano1, Sumito Ito2, Xuan Zhang2, Hiroshi Ito3, Ming-Rong Zhang4, Hiroshi Suzuki5, Kazuya Maeda2, Hiroyuki Kusuhara6, Tetsuya Suhara4, Yuichi Sugiyama7.
Abstract
We synthesized [11C]sulpiride as a positron emission tomography probe for investigating the drug distribution in the human body. [11C]Sulpiride was injected to healthy male subjects in either tracer dose of [11C]sulpiride (approximately 222 MBq) or with therapeutic dose of sulpiride (500 mg, peroral) 3 h before the injection in a crossover fashion. Whole-body positron emission tomography imaging demonstrated that [11C]sulpiride accumulated exceedingly in the bladder, followed by liver, gall bladder, and kidney, respectively, at 30 min after the injection, whereas scarcely in the brain. Oral dose of sulpiride decreased the hepatic accumulation of the radioactivity by 60%. From in vitro experiments, we found that sulpiride is a substrate of hOCT1 (Km 2.6 μM), hOCT2 (Km 68 μM), hMATE1 (Km 40 μM), and hMATE2-K (Km 60 μM). Moreover, the uptake of sulpiride by human hepatocytes was diminished by tetraethylammonium, and saturable with Km of 18 μM. Oct1/2 double knockout mice and wild-type mice received Mate1 inhibitors (pyrimethamine/cimetidine) manifested reduced renal clearance of sulpiride, accompanied with its accumulation in the plasma. In conclusion, we found that sulpiride is a substrate of OCT1, OCT2, MATE1, and MATE2-K, and this suggests that [11C]sulpiride would be a useful radioligand to investigate the organic cation transporters in humans.Entities:
Keywords: PET; distribution; hepatic transport; imaging methods; organic cation transporters (OCTs); renal clearance
Mesh:
Substances:
Year: 2017 PMID: 28499878 DOI: 10.1016/j.xphs.2017.05.006
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.534